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Abstract
Background: In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/
consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European
clinical guidelines and protocols recommend testing patients who achieve a complete hematological remission (CR)
for MRD for the purpose of risk stratification. The aim of this study was to provide quantitative information regarding
real-world clinical practice for MRD testing in five European countries.
Methods: A web-based survey was conducted in March/April 2017 in France, Germany, Italy, Spain, and the UK. The
survey was developed after consultation with specialist clinicians and a review of published literature. Eligible clinicians
(20 per country; 23 in Spain) were board-certified in hemato-oncology or hematology, had at least five years’ experience
in their current role after training, had treated at least two patients with B-cell precursor ALL in the 12 months before the
survey or at least five patients in the last five years, and had experience of testing for MRD in clinical practice.
Results: MRD testing is now standard practice in the treatment of adult ALL across the five European countries, with
common use of recent treatment protocols which specify testing. Respondents estimated that, among clinicians in their
country who conduct MRD testing, 73% of patients in first CR (CR1) and 63% of patients in second or later CR (CR2+) are
tested for MRD. The median time point reported as most commonly used for the first MRD test, to establish risk status
and to determine a treatment plan was four weeks after the start of induction therapy. The timing and frequency of tests
is similar across countries. An average of four or five post-CR1 tests per patient in the 12 months after the first MRD test
were reported across countries.
Conclusions: This comprehensive study of MRD testing patterns shows consistent practice across France, Germany, Italy,
Spain, and the UK with respect to the timing and frequency of MRD testing, aligning with use of national protocols. MRD
testing is used in clinical practice also in patients who reach CR2 + .
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Background
Acute lymphoblastic leukemia (ALL) is a rare hematological
malignancy in adults, with an estimated incidence of 0.62 per
100,000 adult population [1]. Approximately three-quarters
of adult ALL cases are of B-cell lineage, the majority origina-
ting from immature B-lymphocytes (B-precursor ALL), with
or without the Philadelphia chromosome (Ph) translocation
(Ph + or Ph−) [2]. After front-line chemotherapy, the majo-
rity of adults with ALL achieve hematological complete re-
mission (CR, defined as < 5% lymphoid blasts in the bone
marrow based on a morphologic assessment) [3]. However,
leukemic cells may remain in the bone marrow below the
threshold of detection of conventional morphologic methods;
this is termed minimal residual disease (MRD) [4].
MRD testing uses biomarkers of malignant cells to
identify trace levels in bone marrow samples from
patients who have achieved CR, using flow cytometry or
polymerase chain reaction (PCR)-based techniques [5].
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Large prospective multicenter studies have found that
33–47% of patients have MRD after induction therapy
[6–9]. Large-scale studies have shown a strong associ-
ation between the presence of MRD after front-line
therapy and poor long-term outcomes, including an
increased risk of relapse and shorter relapse-free,
disease-free, and overall survival [6, 8, 10, 11]. An
analysis of studies by the German Multicenter Study
Group for Adult ALL indicated that the five year
overall survival rate for patients in CR with MRD
after consolidation therapy was 42%, compared with
80% for patients in CR without MRD [8]. A
meta-analysis of the association of MRD with clinical
outcomes reported 64% of adult patients without
MRD were estimated to be event-free at 10 years
compared with 21% with MRD. Similarly, the absence
of MRD was associated with a 72% reduction in the
risk of death; 10-year survival was estimated as 60%
compared with 15% [12]. Allogeneic stem cell trans-
plantation (SCT) is an option for patients in
hematological CR with MRD but these patients have
at least a 70% higher risk of both hematological
relapse and death 3 years after SCT than patients
without MRD [13–16].
European clinical guidelines and protocols recommend
testing adult patients with ALL in first CR (CR1) for
MRD to inform risk stratification which drives treatment
decisions [17–22]; however, it is unclear to what extent
this is reflected in clinical practice. The rationale for this
study was to provide quantitative, up-to-date informa-
tion to describe real-world clinical practice for MRD
testing in five European countries (France, Germany,
Italy, Spain, and the UK) in adult patients with
B-precursor ALL. The objectives were to determine the
treatment practices of respondents with respect to use
of treatment protocols, timing of MRD tests, methods of
testing, frequency of testing, and how the outcomes of
MRD testing influence treatment decisions for patients,
with both Ph − and Ph + disease.
Methods
A cross-sectional web-based survey of clinicians who
specialize in the treatment of adults with ALL was
conducted over an eight week period in March/April
2017 (an initial pilot survey was conducted in Janu-
ary 2017). The Human Research Ethics Committee
of the University of Technology, Sydney, Australia,
granted ethics approval, and all participants gave
written informed consent before starting the survey.
Further details on the methodology of the web-based
survey are reported in line with the Checklist for
Reporting Results of Internet E-Surveys (CHERRIES)
[23] (Additional file 1).
Questionnaire development
The content of the questionnaire was informed by a re-
view of clinical guidelines, treatment protocols for ALL,
and publications [24–32]. The draft questionnaire was
reviewed by an advisory panel comprising one clinical
expert in the use of MRD testing in ALL from each of
the five countries. The questionnaire mainly comprised
questions with categorical answers and numerical re-
sponses, with some follow-up questions requesting
free-text responses. The questionnaire included the fol-
lowing topics: participant background, use of treatment
protocols (defined in the survey as a published set of
rules, often endorsed by a research institution or a
clinical body, such as a hematology group), proportion
of patients tested for MRD, marker identification for
later MRD testing, details of MRD testing in front-line
treatment and use of MRD testing in patients with prior
relapse. With respect to the MRD testing in front-line
treatment, details were asked about the timing and
methodology of the “prognostic” MRD test (defined in
the survey as the MRD test used to establish risk status
and to determine a treatment plan) and subsequent
MRD tests. Respondents were asked to report MRD test-
ing patterns according to the Ph+/Ph − status of patients.
The questionnaire was programmed for online use and
translated into local languages. The questionnaire is
included as Additional file 2.
Participant recruitment
Study participants were recruited by an external medical
fieldwork agency from a panel of clinicians who had
agreed to participate in such research. Eligible partici-
pants, for both the pilot and the main phase study, were
board-certified in hemato-oncology or hematology; had
at least five years’ experience in their current role after
training; had treated at least two patients with
B-precursor ALL in the 12 months before the survey, or
at least five such patients in the last five years, and had
experience of conducting MRD testing in clinical prac-
tice. An initial e-mail invitation was sent to clinicians
explaining the objective of the study, and a screener
questionnaire then followed to determine the clinicians’
eligibility to participate in the survey. Eligible partici-
pants were compensated for their time (at the fair
market value).
Pilot study
In order to confirm that the questionnaire was easily
understood, well targeted and that it provided infor-
mative results, a pilot phase with a draft version of the
questionnaire preceded the main survey. Two partici-
pants were recruited per country from the same pool of
clinicians subsequently approached in the main phase of
the survey. An additional eligibility criterion was applied
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exclusively for the pilot phase, but was removed given
concerns over misunderstanding and unwarranted exclu-
sion of potential participants: that participants had to
practice in an institution that participated in research
into the treatment of adult patients with ALL conducted
by one of the European ALL study groups, or that
participated in other recent registered clinical trials.
Responses were reviewed and a follow-up telephone
interview was conducted to collect feedback, which was
used to refine the questionnaire for the main survey.
Pilot phase data were not included in the survey results,
and clinicians who participated in the pilot phase were
not approached again for the main survey.
Survey conduct
The web-based survey was completed by eligible partici-
pants without time restrictions and in the local language.
The survey was designed to take around 45 min to
complete.
Statistical analysis
The survey was a descriptive study, and no formal statis-
tical hypotheses were tested. All data were analyzed sep-
arately for each country according to a pre-specified
analysis plan and pooled analyses across all countries
were also conducted. The analyses were performed using
SAS statistical software, version 9.4. Continuous vari-
ables were summarized in the form of mean and stan-
dard deviation (SD) and median and interquartile range
(IQR); both parametric and non-parametric approaches
were used because the mean value may be sensitive to a
few outlying observations due to the small sample size.
For categorical variables, the number and percentage of
respondents was calculated for each category. Free-text
fields were reviewed and categorized.
Results
Demographics and treatment practice of study
respondents
Twenty clinicians per country completed the survey, ex-
cept for Spain where 23 clinicians participated. Across
countries respondents had a mean of 16 years’ experience
in treating ALL since completion of specialty training.
Most respondents reported that their institution was a
university hospital (66%, n = 68), and 78% (n = 80)
reported that their institution participated in research
conducted by a European ALL study group or in other
registered trials (see Additional file 3: Table S1).
Across all five countries, respondents reported that a
mean of 70% (SD 36%; ranging from 50% in the UK to
89% in Spain) of their adult patients receiving front-line
therapy for B-precursor Ph– ALL had their treatment
pathway determined by a protocol. For patients with Ph
+ ALL, a mean of 73% (SD 35%; ranging from 61% in
the UK to 88% in Spain) of patients in the respondents’
caseloads were reported to have their treatment deter-
mined by a protocol. Other patients were reported to
have their treatment determined by an investigational
clinical trial protocol (mean [SD]; 18% [30%] for Ph −
ALL and 14% [25%] for Ph + ALL across countries), or
by neither of these (mean [SD] 12% [24%] for Ph-ALL
and 13% [28%] for Ph + ALL across countries). In the
UK, the proportion of patients whose treatment was de-
termined by an investigational clinical trial protocol were
considerably higher than that across the rest of the
participating countries (Ph- 40% vs Ph + 23%). This may
be due to inconsistencies in whether respondents
categorized the UK ALL 14 study [22] as a protocol or
investigational clinical trial. Respondents selected recent
protocols in their country as their most common choice
to guide front-line treatment; these protocols require
MRD testing (Table 1). The time points for MRD testing
and key recommendations from the protocols are pro-
vided in the supplementary data (see Additional file 3:
Table S3).
Use of MRD testing
Respondents were asked to estimate the proportion of
patients tested for MRD in their country amongst adults
with B-precursor ALL. Across countries, it was esti-
mated that amongst clinicians who test for MRD, 73%
(SD 24%) of patients in CR1 and 63% (SD 27%) in CR2+
are tested for MRD (Figure 1). These results indicate
that MRD testing is common in CR2+ as well as in CR1,
although at a slightly lower rate than in CR1.
Testing in newly diagnosed patients
Marker identification for later MRD testing was reported
as usual practice by the majority of surveyed clinicians.
Across countries, 78% of respondents requested marker
identification for later MRD testing for all their patients
with Ph − disease receiving front-line treatment (ranging
from 70% respondents in France to 90% in the UK); the
corresponding proportion for patients with Ph + disease
was 83% (ranging from 71% in Germany to 90% in Italy).
Respondents who did not report requesting marker
identification for all their patients most frequently
indicated the poor physical status of the patient as the
reason.
Timing of the first prognostic MRD test and methods of
testing
Across countries, the median time point reported as
most commonly used for conducting the first “prognos-
tic” MRD test was 4 weeks (IQR 4–8 weeks) after the
start of induction therapy, for both Ph − and Ph + disease
(see Additional file 3: Table S4). Across countries, clini-
cians reported that they requested prognostic MRD tests
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based on PCR for 64% (SD 40%) and 69% (SD 40%) of
their patients in CR1 with Ph − and Ph + disease, re-
spectively. The corresponding figures for MRD tests
based on flow cytometry were 50% (SD 43%) and 41%
(SD 44%), respectively (Figure 2). The results indicated
that some clinicians use more than one method of testing.
A similar mix of technologies were used for Ph − and Ph +
disease in all countries except in Spain, where use of flow
cytometry predominated for Ph − disease. Clinicians were
further asked whether this test was conducted at a central
laboratory, and/or a local laboratory. For patients in CR1
with Ph − disease, the majority of clinicians in all countries
reported using central laboratories for testing, with or with-
out local laboratory testing in addition, ranging from 89%
in France to 52% of respondents in Spain. For patients in
CR1 with Ph + disease, the majority of respondents
reported using central laboratories, with or without local
laboratory testing, in all countries except Spain (see
Additional file 3: Table S5).
Treatment decisions based on prognostic test results
For patients with MRD− status determined by the prog-
nostic test, the most commonly reported treatment
decision guided by this result was to start mainten-
ance or consolidation treatment (selected by 82% of
respondents for Ph − disease [ranging from 72% in
France to 92% in Italy] and 72% respondents for Ph +
disease [ranging from 61% in the UK to 78% in
France]). Across countries, 28 and 41% respondents
(Ph − and Ph + disease, respectively) stated that MRD−
status in the prognostic test would influence the deci-
sion on suitability for SCT, and 26 and 30% reported
that this would indicate the start of treatment intensi-
fication (see Additional file 3: Table S6).
For patients with MRD+ status determined by the
prognostic test, the most commonly reported treat-
ment decisions were to start treatment intensification
(67% of respondents for Ph − and 61% for Ph + dis-
ease) and to decide suitability for SCT (59% respon-
dents for Ph − and 62% for Ph + disease), both
aligning with recommendations that MRD+ status
should be considered an indication for more intensive
treatment. MRD+ status was reported to indicate the
start of maintenance or consolidation treatment by
less than one third of the respondents (see Additional
file 3: Table S6).
Table 1 Protocols selected as the most common choice
Protocol/trial (% of responding clinicians selecting protocol/trial as most common choice)
Adults with Ph − disease Adults with Ph + disease
France GRAALL 2014 50 ALL GRAALLPHAG06/EWALL-PH–01 35
Germany GMALL 08 2013 65 GMALL 08 2013 65
Italya GIMEMA LAL1913 42 GIMEMA LAL1811 25
Spain PETHEMA LAL-AR/2011 57 PETHEMA LAL PH–2008 59
UK UK ALL 14 70 UK ALL 14 68
aUse of a range of GIMEMA protocols was reported for Italy, reflecting different populations (GIMEMA LAL1913, GIMEMA LAL1104, and GIMEMA LAL1308 for Ph −
disease; GIMEMA LAL1811 and GIMEMA LAL1408 for Ph + disease)
ALL, acute lymphoblastic leukemia; Ph, Philadelphia chromosome translocation
Fig. 1 Estimated proportion of adults with B-precursor ALL tested for MRD amongst clinicians who test for MRD. Footnote: ALL, acute
lymphoblastic leukemia; CR1, first complete remission; CR2+, second complete remission or later; MRD, minimal residual disease
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Frequency of post-CR MRD testing
Clinicians reported that they most commonly conducted
an average of four or five tests per patient in the
12 months after the prognostic test (Table 2). The aver-
age number of tests was reported to be lower in patients
with MRD+ than with MRD− status in most countries
(Table 2). The mean frequency of testing across coun-
tries was every four months in patients with Ph − disease
and MRD+ status, every two months in patients with
Ph + disease and MRD− status, and every three months
in other groups (data not shown).
Testing in patients in CR2 and later
Across countries, 86% of respondents (ranging from 80%
in the UK and Italy, to 100% in France) indicated that
they had conducted MRD testing in patients in CR2+ in
the last 12 months; these clinicians were asked about the
reasons, and the frequency of MRD testing in these pa-
tients. The most commonly reported reasons in patients
with prior relapse were to monitor for progression (26%
of respondents), to offer additional therapeutic options
(22%), and to inform decision-making on SCT (19%).
The median frequency of testing was reported to be
every three months (IQR 2–3) across countries.
Discussion
To our knowledge, this is the first comprehensive study
of patterns of MRD testing in adult ALL in Europe. The
survey has shown that MRD testing is now standard
practice in the treatment of adult ALL across the five
European countries included. This is consistent with the
common use in these countries, as identified in this
survey, of recent national protocols that recommend
MRD testing to inform treatment decisions. The results
suggest that only a small proportion of patients are not
tested for MRD on achieving CR1, which is likely to be
due to individual clinical reasons such as poor physical
status (the most common reason provided in the survey).
Fig. 2 Method used for MRD testing for patients in CR1 for prognostic MRD test. Footnote: CR1, first complete remission, MRD, minimal residual
disease; PCR, polymerase chain reaction; Ph, Philadelphia chromosome translocation
Table 2 Most common number of post-CR tests over 12 months after the prognostic MRD test
Adults with Ph − disease Adults with Ph + disease
MRD− MRD+ MRD− MRD+
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
France 3 (3) 3 (2–3) 3 (2) 2 (2–3) 4 (5) 3 (2–4) 3 (4) 2 (2–3)
Germany 5 (5) 3 (2–4) 4 (4) 2 (2–6) 5 (5) 3 (2–4) 4 (5) 3 (2–5)
Italy 6 (6) 4 (3–7) 6 (4) 4 (3–6) 6 (6) 4 (3–6) 5 (6) 4 (2–6)
Spain 5 (2) 5 (3–6) 4 (2) 3 (3–6) 5 (2) 5 (3–6) 4 (2) 3 (3–6)
UK 6 (5) 4 (2–8) 5 (5) 3 (2–6) 5 (4) 4 (3–8) 6 (5) 4 (3–7)
Across countries 5 (4) 4 (2–6) 4 (4) 3 (2–5) 5 (4) 4 (3–6) 5 (5) 3 (2–5)
CR, complete remission, MRD, minimal residual disease; Ph, Philadelphia chromosome translocation; SD, standard deviation; IQR, interquartile range
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MRD testing practices are broadly similar across the
countries in terms of timing, frequency, and technology of
tests, reflecting broad alignment between national proto-
cols, except in Spain, where flow cytometry rather than
PCR was reported as more commonly used for patients
with Ph − disease.
However, the survey identified small differences in the
number of MRD tests conducted in patient groups based
on their initial MRD status in clinical practice: the lower
number of tests in patients with MRD+ status may re-
flect the use of SCT in these patients, with the frequency
of MRD testing after SCT not specified by protocols and
potentially less; alternatively it may reflect poorer
survival in these patients.
The survey identified that MRD testing in clinical
practice is commonly used in patients in CR2+ as well
as in CR1. This was somewhat unexpected given that
the treatment pathway for patients with prior relapse is
not driven by standard protocols in most countries,
hence MRD testing in that setting is not protocol driven.
In Spain, the PETHEMA group has published a protocol
for the treatment of relapsed ALL that recommends
MRD testing for younger patients who will undergo
SCT: the results of this survey suggest that there is high
use of this protocol. The survey suggests that MRD
status is of interest for clinicians treating relapsed ALL,
although our results indicate that the clinical rationale
and implications of this vary between clinicians (MRD
status was reported to be used for prognosis, monito-
ring, or to inform treatment decisions).
As well as being the first study to comprehensively
assess MRD testing patterns in Europe, this study has sev-
eral other strengths. The methods for survey development
were robust, involving a thorough review of guidelines
and the literature, as well as seeking input from clinicians.
A pilot survey was conducted to ensure the validity of the
survey. The number of participants was pre-specified for
each country, to ensure the data collected were represen-
tative and accurate. Finally, participants had to meet strin-
gent inclusion criteria to ensure they had extensive
experience of treating B-precursor ALL and MRD testing
in clinical practice.
The study also had some potential limitations. The
results presented here were based on clinicians’ esti-
mates, not patient-level observations. Respondents
were recruited through a medical fieldwork agency,
from a pool of clinicians who had previously indi-
cated their willingness to participate in online re-
search; this pool may not be representative of all
clinicians who treat ALL in each country. However,
given the limited number of clinicians treating adult
patients with ALL in each country, we are confident
that with our sample size, our results can reflect the
national practice patterns in general. This survey also
only included clinicians in five larger Western
European countries: local protocols and availability of
testing technologies may differ elsewhere and mean
these results may not reflect European clinical prac-
tice as a whole.
Further we have observed some results that suggest
misinterpretation of specific questions.
 The current Spanish protocols (from PETHEMA),
and known availability of testing technologies in this
country, means that we would expect the vast
majority of clinicians in Spain treating ALL to report
use of flow cytometry for their patients with Ph–
disease; the results showed that flow cytometry
indeed was more commonly used, but an average of
28% of respondents’ caseloads of Ph– patients were
reported to have samples tested by PCR; this was
higher than expected. For Ph + disease, PCR-based
detection of the characteristic BCR-ABL fusion gene
had been expected to be used for all patients in line
with protocols, but flow cytometry was reported to
be used for 45% of respondents’ caseloads.
 A minority of respondents provided illogical
responses when asked about the treatment decisions
following a negative prognostic MRD test
(respondents reported that they would intensify
treatment in 26% of patients with Ph– and 30% of
patients with Ph + disease): as treatment
intensification would not be a logical consequence of
this result, we assume that these respondents
misinterpreted the question.
Such limitations may arise from the methodology used
– for example, there was no opportunity for dialogue or
clarification during or after completion of the survey. Al-
though this avoids potential bias to report ideal rather
than actual practice, it also meant that unexpected re-
sults could not be investigated further to determine
whether they reflected misinterpretations or mistakes in
completing the survey. A more open, interview-based
approach may be preferable in the future for such a
specialized disease area to avoid these issues.
A next step in this research would be to extend the cli-
nical interpretation of the results through focused discus-
sions with practicing clinicians in each country, including
identifying where and why differences arise, and when
more individualized (at a patient or institution-level) treat-
ment decisions are needed; such discussion could inform
the development of future protocols. MRD testing in
clinical practice may be sensitive to future changes in
technology and treatments, including increased
standardization within and across countries as a result of
collaborative initiatives and new treatments indicated by
MRD status; also if increasing risk stratification of ALL
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patient populations leads to different risk-based treatment
pathways for patient subtypes, e.g., Ph-like ALL. It would
be useful to address these issues again at a later date, to
increase understanding of the best way to use MRD
testing in risk evaluation and treatment decision-making.
Conclusions
This study provides estimates of the extent of MRD test-
ing and protocol use in France, Germany, Italy, Spain,
and the UK. The timing and frequency of MRD testing
in clinical practice is consistent across the countries, as
is the use of MRD testing outcomes to guide treatments
decisions. The prevalence of testing differs between pa-
tients with MRD+ and MRD− status, with fewer tests in
the former group.
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